OSL •
Healthcare •
Biotechnology •
Quote as of 05/29/2026 16:29
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeOSL
Market Capitalization2,372.71 mln
Float180 mln
Earnings Date04/15/2026
Piotroski F-Score
2
/ 9
Weak
Relative Strength
4
/ 100
Severely lagging
Debt / Equity
-0.67
Negative equity
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Payout Ratio
0%
No payout
Business Description
Circio Holding ASA is a Norwegian biotechnology company, founded in 2010 and headquartered in Oslo, that focuses on developing cancer treatments based on circular RNA technology and immunotherapy. Its lead program, TG01, is a cancer vaccine designed to target specific cancer-driving mutations and is currently being tested in clinical trials for multiple myeloma, pancreatic cancer, and lung cancer. The company's circVec platform is used to engineer functional circular RNA molecules inside human cells, with ongoing partnerships supporting both its formulation and the development of a macrophage-based cell therapy approach to fighting cancer.
